INTERNATIONAL LIVER CANCER ASSOCIATION

International Liver Cancer Association 17th Annual Conference

 

7-9 September, Amsterdam
Close
N. Poster
Poster title
Applicant name
Status
  P-01 Multimodal and spatial analysis of tumour-immune microenvironment in steatosis-driven hepatocellular carcinoma Aldo Prawira Received Received
  P-02 Inhibition of PARP-1 in KRAS-mutated intrahepatic cholangiocarcinoma exerts positive effects and is mediated by CHK1 kinase Darko Castven Received Received
  P-03 Hypoxia promotes adenosine efflux to establish the immunosuppressive microenvironment in liver cancer Carmen Wong Received Received
  P-04 Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma Binghua Li Received Received
  P-05 Integrated genomic analysis refines molecular classifications of hepatocellular carcinoma based on LICA-FR cohort of 529 samples Long Pan Received Received
  P-06 The senescent secretome drives the re-emergence of the fetal receptor PLVAP on human hepatic endothelium to promote monocyte transmigration. Shishir Shetty Received Received
  P-07 Inactivation of histone chaperone complex CAF-1 elicits intrinsic anti-cancer immunity through activating the cytosolic DNA and dsRNA sensing pathways in hepatocellular carcinoma Chun-Ming Wong Received Received
  P-08 Outcome of Targeting ATR in High Replication Stress murine HCC JING FANG Received Received
  P-09 Genetic and pathologic features of papillary neoplasms of human biliary system of intrahepatic and extrahepatic bile ducts and gallbladder Young Nyun Park Received Received
  P-13 Financial and Psychological Burden of HCC Surveillance in Patients with Cirrhosis Amit Singal Received Received
  P-14 Achievement of Cancer and Drug-free Status by Atezolizumab Plus Bevacizumab Followed by Curative Conversion in Patients with TACE-Unsuitable, Intermediate-stage HCC: A Multicenter Proof-of-Concept Study Masatoshi Kudo Received Received
  P-15 VETC (vessel that encapsulate tumor cluster) EVALUATED IN LIVER BIOPSY PREDICTS ANTI-ANGIOGENIC BENEFIT IN ADVANCED HCC Luca Di Tommaso Received Received
  P-17 Association with body mass index and risk of hepatocellular carcinoma according to liver disorder status HEEJAE JUNG Received Received
  P-19 Drug-eluting beads vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A Randomized Clinical Trial Jun-Hui Sun Received Received
  P-20 Prospective study of surveillance non-contrast abbreviated MRI for hepatocellular cancer in patients with suboptimal hepatic visualisation on ultrasound Mathew Vithayathil Received Received
  P-22 Genomic characteristics of hepatocellular carcinoma patients with response to sorafenib Sun Young Yim Received Received
  P-24 Cytokine levels and circulating DNA in plasma could be used as serological biomarkers of response to immunotherapy in hepatocellular carcinoma Beatriz Mínguez Received Received
  P-25 Preliminary Safety Results of a Phase 1/2 Open-label Study on an Anti-GPC3 T-cell Engager, SAR444200, in Patients with Advanced Solid Tumors Asma Kefsi Received Received
  P-27 Constructing and Experimentally Validating a Disulfidptosis-related Ferroptosis Gene-driven Machine Learning Prognostic Risk Model for Liver Cancer Cong Zhang Received Received
  P-28 Serine utilization and generation of different lipid species influence the response of hepatocellular carcinoma to lipid depletion Bichitra Paul Received Received
  P-31 B-CATENIN PATHWAY MUTATIONS PREDICT FAVORABLE OUTCOMES AFTER TRANSARTERIAL CHEMOEMBOLIZATION IN UNRESECTABLE HEPATOCELLULAR CARCINOMA Kelley Weinfurtner Received Received
  P-32 Lipid-Associated TREM2 Macrophages Mediates Immunosuppressive Microenvironment in Liver Metastasis of Colorectal Cancer Pengxiang Wang Received Received
  P-33 Identification of novel phosphoproteomic biomarkers in patients with advanced hepatocellular carcinoma (HCC) Federico Pedicona Received Received
  P-34 Evaluation of Src family of tyrosine kinases and their potential as molecular targets in overcoming liver cancer heterogeneity Loraine Kay Cabral Received Received
  P-35 Inflammation induced IgA upregulates PD-L1 in cancer associated fibroblasts of HCC and attenuates CD8 T cell function Sung Woo Cho Received Received
  P-36 Nanosecond pulsed electric field ablation of sequential endothelial progenitor cell-directed endothelial inhibitor/suicide fusion gene for the treatment of hepatocellular carcinoma Li Jing Received Received
  P-37 Combinations of fostrox (MIV-818), a novel nucleotide prodrug, with lenvatinib or sorafenib shows increased efficacy in nonclinical hepatocellular carcinoma (HCC) models in vivo Fredrik Oberg Received Received
  P-38 Impact of exosomal miR-4669 on tumor cell behavior and immunosuppressive tumor microenvironment in hepatocellular carcinoma Toshiaki Nakano Received Received
  P-39 New insight in HCC immuno-vascular microenvironment: interplay between tumoral macrophages and VETC Camilla De Carlo Received Received
  P-40 Functional dissection of immune infiltrate reveals that HCC enriched VETC vascular phenotype is characterized by the presence of exhausted T cells. Barbara Durante Received Received
  P-41 Poor sorafenib response in hepatocellular carcinoma is mediated by hypoxia-associated 14-3-3 scaffolding proteins with observed alterations in immune micromilieu Jovana Castven Received Received
  P-42 Synergistic antitumor activity of lenvatinib and lipophilic statins in hepatocellular carcinoma Hyeyeon Hong Received Received
  P-44 GDF11 reduces aggressive behavior provided by tumor-associated macrophages on HCC-derived cells. Oscar Alejandro Escobedo Calvario Received Received
  P-45 Effect of Zinc Acexamate treatment in hepatocellular carcinoma in vitro and in vivo models Beatriz Mínguez Received Received
  P-46 Identification of the epidrivers facilitating hepatocellular carcinoma recurrence Hyun Goo Woo Received Received
  P-47 Gene regulatory network analysis on snRNAseq revealed key regulators for hepatocellular carcinoma progression Su Jong Yu Received Received
  P-48 Lenvatinib induced cell death of hepatocellular carcinoma by increasing HIF-a degradation under hypoxic condition Sung Won Chung Received Received
  P-50 CD73 expression on liver endothelium is promoted by tumour associated stimuli and could contribute to the immunosuppressive microenvironment in hepatocellular carcinoma Rosemary Faulkes Received Received
  P-51 Fructose promotes chemoresistance through the induction of a metabolic rewiring in liver cancer cells and a KHK-A/p27 non-canonical pathway. Lisette Chávez Rodríguez Received Received
  P-52 LI-RADS classification of proliferative hepatocellular carcinomas and its implication on prognosis Subin Heo Received Received
  P-54 The Outcomes of Patients with Hepatocellular Carcinoma and with Child-Turcotte-Pugh Class B Chia Chu Fu Received Received
  P-55 Prediction of Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients following HBsAg seroclearance Jonggi Choi Received Received
  P-56 Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC Federico Piñero Received Received
  P-58 Tumor response-based nomogram for ion of patients with hepatocellular carcinoma benefitting from drug-eluting bead transarterial chemoembolization Cong Zhang Received Received
  P-59 Effect of chemotherapeutic agents on acute kidney injury in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: doxorubicin versus cisplatin Won Sohn Received Received
  P-60 Treatment outcomes in patients with advanced fibrolamellar hepatocellular carcinoma: analysis of clinical characteristics and radiomics phenotypes Leonardo da Fonseca Received Received
  P-63 Implication of patients experience in the liver cancer multidisciplinary approach Gemma Iserte Received Received
  P-65 Sarcopenia affects the therapeutic efficacy of immunotherapy for advanced Hepatocellular carcinoma. Takuya Kuwashiro Received Received
  P-68 Consistent efficacy of Hepatic Artery Infusion Chemotherapy irrespective of PD-L1 positivity in unresectable hepatocellular carcinoma Ji Hoon Kim Received Received
  P-69 Differences in Outcomes Between Screen-Detected and Non-Screen Detected Hepatocellular Carcinoma Darine Daher Received Received
  P-71 Correlates and Outcomes of CT or MRI-based Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis Darine Daher Received Received
  P-72 Clinical Performance of GAAD and GALAD Algorithmic Scores for Hepatocellular Carcinoma (HCC) surveillance in Patients with Chronic Hepatitis Ming-Lung Yu Received Received
  P-74 Discrepancy between the real clinical status of patients with HCC and expectations from HCC surveillance: a single center study Jiwoong Jang Received Received
  P-75 Peripheral immune markers can detect hepatocellular carcinoma in blood in a Latin American cohort Andre Boonstra Received Received
  P-76 Evaluation of the Accuracy of Imaging Diagnosis for Hepatocellular Carcinoma in Chronic Hepatitis C Patients without Liver Cirrhosis Jihyun An Received Received
  P-80 Differentiation of Primary Malignant Vascular Tumors using CT and Gadoxetate-enhanced Liver MRI So Yeon Kim Received Received
  P-81 Pan-viral serology uncovers distinct virome patterns among hepatocellular carcinoma and control populations Whitney Do Received Received
  P-82 Role of Tumor Markers in Diagnosing Recurrent Hepatocellular Carcinoma after Curative Resection Jeong Ah Hwang Received Received
  P-83 Performance of tumor-specific microRNAs as plasma biomarkers of hepatocellular carcinoma in patients with liver cirrhosis Robin Zenlander Received Received
  P-85 Five-year on-treatment parameters-based model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir-treated patients Yeonjung Ha Received Received
  P-86 Evaluating performance of aMAP score in predicting hepatocellular carcinoma development over a two-year period in cirrhosis patients Avisnata Das Received Received
  P-89 Early detection of hepatocellular carcinoma using urinary metabolomic biomarkers in an Australian Aboriginal population. Paula Binks Received Received
  P-90 Physician and patient survey of practices and perspectives in the surveillance and diagnosis of hepatocellular carcinoma (HCC) in Asia: unmet needs in the real world Iain Murdoch Received Received
  P-91 IMbrave050: Phase 3 study of adjuvant atezolizumab bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation Elyse Viana Received Received
  P-92 Risk of Gastrointestinal Bleeding in Patients Receiving AtezolizumabBevacizumab Treatment for Hepatocellular Carcinoma Jonggi Choi Received Received
  P-93 Real-world (RW) systemic treatment patterns in US patients (pts) with hepatocellular carcinoma (HCC): 20202022 Rego Team Received Received
  P-94 Systemic Treatment in Child Pugh B Patients with Hepatocellular Carcinoma Kevin Mok Received Received
  P-95 Semaglutide, but not lanifibranor, promotes tumor regression in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC Denise Oró Received Received
  P-96 Metabolic dysfunction associated fatty liver disease and the risk of hepatocellular carcinoma BYEONGGEUN SONG Received Received
  P-97 Randomized phase II trial to assess safety and efficacy of regorafenib in patients with advanced hepatocellular carcinoma who were not included in the RESORCE trial: REGAIN trial Keisuke Koroki Received Received
  P-98 A Study on the Sequence of Systemic Treatment in Hepatocellular Carcinoma Kevin Mok Received Received
  P-99 Macrotrabecular-Massive pattern is associated with aggressive factors, but it is not an independent predictor of tumor recurrence and overall survival in patients with hepatocelular carcinoma treated with liver resection Ezequiel Mauro Received Received
  P-100 Validation of Baveno-VII criteria for clinically significant portal hypertension in patients with compensated advanced chronic liver disease BYEONGGEUN SONG Received Received
  P-101 The predictive value of liver volume on hepatic decompensation and the long-term effects of stereotactic body radiation therapy on hepatic decompensation JINHONG JUNG Received Received
  P-102 A prospective study to evaluate the safety and efficacy of lenvatinib in patients with advanced hepatocellular carcinoma to maximise its potential in current practice Kazufumi Kobayashi Received Received
  P-104 Real-time US-CT/MR Fusion Imaging-guided Anatomical Ablation for Small Hepatocellular Carcinomas Using Multiple Applicators: A Preliminary Study Jae Hyun Kim Received Received
  P-105 Glypican-3-targeted radiopharmaceutical therapy for hepatocellular carcinoma: Preclinical characterization of a novel peptide radioligand Fanching Lin Received Received
  P-107 A Multicenter Propensity Score Matching Analysis of the Clinical Outcome of Atezolizumab/Bevacizumab and Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Comparative study Hee Sun Cho Received Received
  P-108 Single arm study to evaluate the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma patients in Japanese real-world practice; focusing on the complement of the REACH-2 study: R-evolution trial Kazufumi Kobayashi Received Received
  P-109 Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance Marco Sanduzzi Zamparelli Received Received
  P-110 Lung-specific response to atezolizumab plus bevacizumab is associated with overall survival in patients with lung metastasis from hepatocellular carcinoma Ju Hyun Shim Received Received
  P-111 Clinical Outcomes of Stereotactic Body Radiation Therapy Alone versus Stereotactic Body Radiation Therapy after Incomplete Transarterial Chemoembolization for a Single Small (= 5 cm) Recurrent Hepatocellular Carcinoma JINHONG JUNG Received Received
  P-112 Metastasectomy versus stereotactic body radiation therapy for pulmonary oligometastasis from hepatocellular carcinoma: a propensity score-weighted analysis Sang Min Yoon Received Received
  P-113 Palliative care in patients with BCLC-D hepatocellular carcinoma not indicated for liver transplantation: results of a survey among Italian hepatologists and palliative care physicians. Lorenzo Canova Received Received
  P-114 Portal-hypertension parameters are associated with transplantation free survival and ascites occurrence in patients with hepatocellular carcinoma treated by external radiotherapy Héloïse Giudicelli Received Received
  P-115 Significance of autoantibody assay in patients receiving atezolizumab and bevacizumab combination therapy for unresectable hepatocellular carcinoma Hitomi Takada Received Received
  P-117 Value based Healthcare: Patient perception of the liver cancer Advanced Practice Nurse care at the Barcelona Clinic Liver Cancer Neus Llarch Received Received
  P-118 Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation Jai Young Cho Received Received
  P-119 A real-world comparative analysis of atezolizumab plus bevacizumab and transarterial chemoembolization plus radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombosis Jong Young Choi Received Received
  P-123 Liver-directed combined radiotherapy for downstaging of over the Milan advanced hepatocellular carcinoma converting to liver transplantation jinsil seong Received Received
  P-124 Comparative Analysis of combination therapy (Atezolizumab bevacizumab) and hepatic artery infusion chemotherapy in Unresectable Hepatocellular carcinoma: A multi-center study Ji Hoon Kim Received Received
  P-126 The efficacy and safety of Toripalimab combined with Sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study Xin-Rong Yang Received Received
  P-127 Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma Judith Land Received Received
  P-128 Association of alcohol consumption with liver cancer and all-cause mortality in chronic hepatitis B patients without cirrhosis Beom Kyung Kim Received Received
  P-129 FGFR2 Pathway Activation Beyond The Alteration of FGFR Receptor in Intrahepatic Cholangiocarcinoma Chiara Deiana Received Received
  P-130 Differential risk of hepatic events during immune checkpoint inhibitor treatment between hepatocellular carcinoma and other malignancies Yi-Hsiang Huang Received Received
  P-131 The expression of Aurora kinase A in hepatocarcinogenesis and its role in Programmed DeathLigand 1 regulation Luca Grisetti Received Received
  P-132 Weakly supervised primary liver cancer classification from routine tumour biopsy: a proof of concept Aurélie Beaufrère Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
07:03
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

International Liver Cancer Association 17th Annual Conference

 

7-9 September, Amsterdam
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 06/09/2023 TO 07/09/2024
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert